|
Wednesday, 3 September |
|
8.00-9.00 |
PRESENTATIONS
POSTER VIEWING
reception hall, 3rd floor |
|
|
Poster Presentations |
|
9.00-11:00 |
SECOND PLENARY SESSION |
|
9:00 9:15 |
INTERNATIONAL COMPARISON OF HEALTH CARE
REIMBURSEMENT SYSTEMS AND USE OF PHARMACOECONOMICS IN THE
REIMBURSEMENT PROCESS
international conference room 301
Moderator: Kenneth KC Lee PhD,
Professor & Head, Division of Pharmacy Practice, Pharmacy Department,
The Chinese University of Hong Kong, Shatin, Hong Kong
|
|
9:15 9:30 |
HEALTH CARE
REIMBURSEMENT SYSTEMS AND USE OF PHARMACOECONOMICS IN JAPAN
Speaker:
Makoto Shiragami PhD, Nihon University, College of Pharmacy,
Social and Administrative Pharmacy Science, Chiba, Japan
|
|
9:30 9:45 |
HEALTH CARE REIMBURSEMENT SYSTEMS AND
USE OF PHARMACOECONOMICS IN CHINA
Speaker: Zhiqiang Guan MD, Head of
Health Insurance Research Department, National Institute of Social
Insurance, Ministry of Labor and Social Security, Beijing, China
|
|
9:45 10:00 |
HEALTH CARE REIMBURSEMENT SYSTEMS AND
USE OF PHARMACOECONOMICS IN KOREA
Speaker: Bong-min Yang PhD, Seoul
National University, School of Public Health, Seoul, Korea |
|
10:00 10:15 |
HEALTH CARE REIMBURSEMENT SYSTEMS AND
USE OF PHARMACOECONOMICS IN SINGAPORE
Speaker: Shu Chuen Li MBA, PhD,
Assistant Professor, Department of Pharmacy, National University of
Singapore, Singapore, Singapore
|
|
10:15 10:30 |
HEALTH CARE REIMBURSEMENT SYSTEMS AND
USE OF PHARMACOECONOMICS IN THAILAND
Speaker: Nathorn Chaiyakunapruk PharmD,
PhD, Instructor, Naresuan University, School of Pharmacy,
Pitsanuloak, Bangkok
|
|
10:30 10:45 |
HEALTH CARE REIMBURSEMENT SYSTEMS AND
USE OF PHARMACOECONOMICS IN TAIWAN
Speaker: Yen-Huei (Tony) Tarn PhD,
Associate Professor, School of Pharmacy, National Defense Medical
Center, Taipei, Taiwan
|
|
10:45 11:00 |
Question & Answer |
|
11:00-11:30 |
BREAK AND
PRESENTATION POSTER VIEWING |
|
|
Poster Presentations |
|
11:30-12:30 |
WORKSHOP
SESSION III
(4 concurrent sessions) |
|
|
Clinical Studies
room 402, 4th floor |
|
W9 |
NUMBER NEEDED TO TREAT (NNT):
IS IT A USEFUL BENCHMARK FOR THE EFFICIENCY OF THERAPIES?
Caro J1, Huybrechts K1, Kamae I2,
1Caro Research Institute, Concord, MA, USA;
2Kobe University, Kobe, Japan
Learning Objective:
In this workshop, origin and
properties of NNT will be reviewed and methods will be examined to
indicate if they meet criteria for a useful decision-making tool.
Workshop Description: The NNT the
reciprocal of the absolute risk reduction was introduced in 1988 as
an "easily understood yardstick to describe the harm as well as the
benefit of therapy and other clinical maneuvers". Although presented
as a tool to facilitate clinical decision-making, its use in public
decision-making was already hinted at in this first publication. The
NNT has since been portrayed as a first approximation to more complex
measures such as cost-utility ratios, which are considered the
ultimate goal of Evidence Based Medicine, and NNT-based league tables
have been presented. In this workshop we will review the origin and
properties of the NNT and evaluate whether it indeed meets the
criteria of a useful decision-making tool: comparative, easy to
understand and calculate, standardized. Although the first three
criteria appear to be met, we will demonstrate how the modifications
proposed over the years to address the shortcomings of the original
NNT in terms of standardization have greatly increased its complexity
while major issues of standardization remain. We will also introduce a
new odds method to address the common misinterpretation that treating
the number of patients implied by the NNT will "certainly" instead
of "statistically" prevent one adverse event. Throughout this
critical evaluation phase, direct input from the workshop participants
will be solicited. We will conclude by presenting our approach to
calculate an "adjusted" NNT for public health use.
|
|
|
Pharmacoeconomics
room 403, 4th floor |
|
W10 |
COST OF ILLNESS
STUDIES: TOP DOWN OR BOTTOM UP?
Einarson T1, Iskedjian M2,
1University of
Toronto, Toronto, ON, Canada;
2PharmIdeas Research and Consulting Inc,
Oakville, ON, Canada
Learning Objectives: Review and examine
cost of illness studies while being able to provide assessment to
selected published studies.
Workshop Description: Among topics to be
covered will be: definitions/types (cost of illness, burden of
illness), types of outcomes (economic, clinical, humanistic), resource
determination, costing and valuation, costing methods (micro-costing,
macro-costing), costing of productivity loss (human capital method,
friction method), level of analysis (global, country, group, patient),
Epidemiologic approach (prevalence, incidence), data collection
approach (top down, bottom up), modelling approach (model,
retrospective, prospective). First part: Formal lecture with examples.
Participants will be provided handouts. Second part: Interactive
hands-on assessment of selected published Cost of Illness studies.
Participants will be provided articles and a checklist for their
assessment.
|
|
|
Quality of Life
room 401 4th floor |
|
W11 |
QUALITY OF LIFE IS
DIFFERENT IN ASIA: ISSUES TO CONSIDER WHEN DEVELOPING AN INSTRUMENT IN
ASIA, EUROPE AND THE US
Abetz L1, Crawford B2;
1Mapi Values, Cheshire, UK;
2Mapi Values, Boston,
MA,
USA
Learning
Objectives: Review methods that
would be acce pt able for use in countries with developing in
struments and provide examples of different and simil ar sit uat
ions noticed in previously conducted research.
Workshop Description: This workshop will
review methods that would be acceptable for use across a range of countries
when developing instruments. Emphasis will be placed on cultural
differences that would require alteration of standardised methods
and ways this can be accomplished without sacrificing scientific
integrity. Specifically, differences and similarities in per forming
qualitative research, developing items, and deciding upon re l e vant
domains will be discussed. Practical examples will be provided by the
workshop leaders, based on their experience. The workshop participants
will also be asked o provide their own examples of differences
and similarities that they have noticed in conducting PRO research.
|
|
|
Health Policy
International Conference Rroom 301, 3rd
floor |
|
W12 |
PHARMACOECONOMICS IN
PRICING AND REIMBURSEMENT IN ASIA-PACIFIC COUNTRIES: THE ISSUES
Liu G1, Guan Zhi-qiang2, Shiragami M3,
Yang BM4, Tarn YH5, 1University
of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2National
Institute of Social Insurance, China, 3Nihon University,
Chiba, Japan, 4Seoul National University, Seoul, Korea, 5National
Defense Medical Center, Taipei, Taiwan
Learning
Objectives: This workshop will
review how pharmacoeconomic data is being used in pricing and
reimbursement policies in several Asia-Pacific countries.
Workshop Description: Pharmacoeconomics
and outcomes research data have been widely used for medic l decision
and health policy making in both private a nd public sectors across
many Western regions, including US, Canada, England, and Australia.
However, little is known about the extent to whi h such data is being
used in Asia Pacific nations. Yet given the strong and growing
economies in this region, it see ms indisputable that the use of
pharmacoeconomics data has a great potential in the Asia Pacific
market. In fact, such a trend has been illuminated by a number of
recent governnment-led healthcare reforms in some Asia Pacific
nations, including Japan, China, Taiwan, Korea, and Singapore. As a
result, pharmacoeconomics data seems to begin playing an increasing
role in national pricing and reimbursement decisions in these nations.
This panel will invite several leading
experts in this area to share theirs views of how pharmacoeconomics
data are being used in pricing and reimbursement policies, and how
they perceive a likely future trend to take place in these nations.
The panel discussion also will serve as a great forum to exchange
information and insights between the panelists and audience on
pharmaceutical pricing and drug formulary decisions in the Asia
Pacific market .
|
|
12.30 13.00 |
CLOSING REMARKS
|
|
|
Presented by Conference Co-chairs:
Isao Kamae MD, DrPH, Kobe University, Kobe, Japan
Naoki Ikegami MD, MA, Keio University, Tokyo, Japan
Shuzo Nishimura PhD, Kyoto University, Kyoto, Japan |
|
|
